Uptake, Impact, and Effectiveness of Rotavirus Vaccination in the United States

Tate, Jacqueline E.; Cortese, Margaret M.; Payne, Daniel C.; Curns, Aaron T.; Yen, Catherine; Esposito, Douglas H.; Cortes, Jennifer; Lopman, Benjamin A.; Patel, Manish; Gentsch, Jon R.; Parashar, Umesh D.

doi:10.1097/inf.0b013e3181fefdc0

Cited by 141 publications

(94 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Remarkable success has been observed not only for vaccines in use for decades, but also for more recently introduced vaccines, including pneumococcal conjugate and rotavirus vaccines. [1][2][3][4][5][6] In addition to the health benefits that have accrued from the US immunization program, cost savings have accrued as well. The first evaluation of the economic impact of all vaccines in the routine US childhood immunization schedule assessed the 2001 schedule (excluding the newly added pneumococcal conjugate and influenza vaccines); this evaluation documented substantial cost savings over the lifetimes of the cohort of children born in 2001.…”

Section: Discussionmentioning

confidence: 99%

Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009

et al. 2014

View full text Add to dashboard Cite

OBJECTIVES: To evaluate the economic impact of the 2009 routine US childhood immunization schedule, including diphtheria and tetanus toxoids and acellular pertussis, Haemophilus influenzae type b conjugate, inactivated poliovirus, measles/mumps/rubella, hepatitis B, varicella, 7-valent pneumococcal conjugate, hepatitis A, and rotavirus vaccines; influenza vaccine was not included. METHODS: Decision analysis was conducted using population-based vaccination coverage, published vaccine efficacies, historical data on disease incidence before vaccination, and disease incidence reported during 2005 to 2009. Costs were estimated using the direct cost and societal (direct and indirect costs) perspectives. Program costs included vaccine, administration, vaccine-associated adverse events, and parent travel and work time lost. All costs were inflated to 2009 dollars, and all costs and benefits in the future were discounted at a 3% annual rate. A hypothetical 2009 US birth cohort of 4 261 494 infants over their lifetime was followed up from birth through death. Net present value (net savings) and benefit-cost ratios of routine childhood immunization were calculated. RESULTS: Analyses showed that routine childhood immunization among members of the 2009 US birth cohort will prevent ∼42 000 early deaths and 20 million cases of disease, with net savings of $13.5 billion in direct costs and $68.8 billion in total societal costs, respectively. The direct and societal benefit-cost ratios for routine childhood vaccination with these 9 vaccines were 3.0 and 10.1. CONCLUSIONS: From both direct cost and societal perspectives, vaccinating children as recommended with these vaccines results in substantial cost savings.

show abstract

Section: Discussionmentioning

confidence: 99%

Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009

et al. 2014

View full text Add to dashboard Cite

show abstract

“…However, a number of full peer-reviewed papers have recently been published with data that are consistent with the preliminary findings reported in the abstracts. [42][43][44] We therefore believe that the use of abstracts provided an accurate representation of vaccine impact at a time when they were the only source of information on this important issue.…”

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tmentioning

confidence: 99%

Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic review of the experience in industrialized countries

Giaquinto¹,

Dominiak-Felden²,

Damme³

et al. 2011

Human Vaccines

View full text Add to dashboard Cite

“…Moreover, no available evidence suggests that either rotavirus diarrhea in US and many other developed nations without significant increase in risk of intussusception. [10][11][12][13][14] Likewise, promising efficacy of rotavirus vaccines was also shown in developing countries. [15][16][17] However, the efficacy was 10-50% lower in developing-country than in developed country settings 15,[18][19][20] and therefore efforts to strengthen healthcare systems must also accompany vaccine introduction.…”

Section: Overview Of Available Rotavirus Vaccinesmentioning

confidence: 99%

“…4 Two rotavirus strains isolated from newborns in India were prepared as candidate vaccines and are under clinical study. Strain 116E is an unusual naturally occurring P [11]G9 human-bovine reassortant strain. A related second neonatal strain (P[11]G10) did not induce protection after its natural infection.…”

Section: Overview Of Available Rotavirus Vaccinesmentioning

confidence: 99%

Rotavirus vaccine: A cost effective control measure for India

Kumar

Goel

Jain

et al. 2012

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Globally, rotavirus diarrhea results in 453,000 deaths in children younger than 5 y-37% of deaths attributable to diarrhea and 5% of all deaths in children younger than 5 y. India alone accounts for 22% (~100,000 deaths) of all deaths attributable to rotavirus infection. Two oral rotavirus vaccines are available: Rotarix, a monovalent P1A[8] G 1 vaccine (GlaxoSmithKline), and RotaTeq, a pentavalent bovine-human reassortant vaccine (Merck). Rotarix is administered in a 2-dose schedule with the first and second doses of DTP (DTP1, DTP2). RotaTeq requires a 3-dose schedule with DTP1, DTP2 and DTP3 with an interval of 4-10 weeks between doses. The first dose of either vaccine should be administered to infants aged 6-15 weeks irrespective of the history of previous rotavirus infection, and the maximum age for administering the last dose of either vaccine should be 32 weeks. Although India would require funding from international health organizations/ GAVI until new indigenous rotavirus vaccine candidates are developed at a cheaper price, introduction of vaccination into the national immunization program would be a cost-effective step toward control of the rotavirus diarrhea-related morbidity and mortality in India.

show abstract

Uptake, Impact, and Effectiveness of Rotavirus Vaccination in the United States

Cited by 141 publications

References 25 publications

Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009

Economic Evaluation of the Routine Childhood Immunization Program in the United States, 2009

Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic review of the experience in industrialized countries

Rotavirus vaccine: A cost effective control measure for India

Contact Info

Product

Resources

About